Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

PR Newswire

LUND, Sweden, May 27, 2026

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submissionIdefirix was generally well tolerated with a safety profile consistent with previous clinical trial experienceSubmission to EMA for conversion to full marketing authorization planned for Q4 2026LUND, Sweden, May 27, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ STOCKHOLM: HNSA), today announced positive topline results from the European 20-HMedIdeS-19 Post Authorization Efficacy Study (PAES), an open-label confirmatory study investigating one-year graft failure-free survival[*] and patient survival in highly sensitized patients who have undergone HLA-incompatible kidney transplantation following desensitization treatment with Idefirix (imlifidase).

View original content:https://www.prnewswire.com/news-releases/hansa-biopharma-reports-positive-efficacy-and-safety-results-from-idefirix-european-post-authorization-study-in-kidney-transplantation-302782744.htmlSOURCE Hansa Biopharma AB